Confirming a KIT mutation and assessing disease spread are critical initial steps for GIST management. Understanding the mutational profile helps tailor treatment, as some mutations may resist Gleevec ...
Gleevec remains effective in advanced GIST, with median overall survival of 75.3 months and significant long-term survival rates. Factors like female sex, gastric tumor location, smaller tumors, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results